Cathie Wood’s ARK Investment continues to capitalize on the pullback in Tempus AI (TEM) stock by accumulating more shares, ...

A remarkable start to the year, marked by a 160% surge, has had investors paying close attention to healthcare tech company ...

The acquisition of Ambry Genetics, finalized in February 2025, further strengthens Tempus’ genomics capabilities by adding a West Coast lab and expanding inherited risk testing. Another ...

For this year, Tempus AI, Inc. (NASDAQ:TEM) expects full-year revenue of approximately $1.24 billion for the consolidated TEM and Ambry Genetics business, which represents approximately 79 percent ...

Tempus AI's Q4 financials were slightly below expectations but aligned with preliminary results. See why I remain bullish on TEM stock.

Despite filing a fourth-quarter and year-end 2024 earnings report that the CEO described as "fantastic" yesterday afternoon, Tempus AI shares fell overnight and a major investment house downgraded ...

Tempus AI demonstrated strong performance in Q4 2024 with a significant revenue increase of 35.8% compared to the previous year. This growth was supported by strategic initiatives such as the ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financia ...

Acquisition: Closed the acquisition of Ambry Genetics on February 3. Google Agreement: Extended for another five years. Tempus AI Inc (NASDAQ:TEM) reported a 35.8% year-over-year revenue growth in ...